Amgen has issued a voluntary recall for nearly 1 million bottles of the heart medication Corlanor (ivabradine) due to possible contamination.

Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is expanding its capacity to manufacture antibody-drug conjugates—and that it has increased the scope of its partnership with a large, unnamed U.S. drugmaker.

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.

After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator.

As BridgeBio ramps up for the launch of three new medicines and continues to channel resources into its soon-to-be-blockbuster in ATTR-CM, Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech.

Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare and life sciences heavyweights turning to Big Tech to execute enterprise-wide digital overhauls.